Feedback
Settings

Settings

Goto Application

1. WO2022139631 - AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY AND/OR PREVENTION OF SARS-COV-2-RELATED INFECTION

Submit observation
PermaLink
Publication Number WO/2022/139631
Publication Date 30.06.2022
International Application No. PCT/RU2021/050447
International Filing Date 21.12.2021
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
C12N 15/50 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
C07K 14/165 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
C07K 1/36 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
14Extraction; Separation; Purification
36by a combination of two or more processes of different types
C07K 1/16 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
14Extraction; Separation; Purification
16by chromatography
CPC
A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
C12N 15/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Applicants
  • JOINT STOCK COMPANY "BIOCAD" [RU]/[RU]
Inventors
  • GERSHOVICH, Pavel Mikhailovich
  • PROKOFYEV, Alexander Vladimirovich
  • STRELKOVA, Anna Nikolaevna
  • SPIRINA, Natalia Aleksandrovna
  • SHUGAEVA, Tatiana Evgenievna
  • IAKOVLEV, Pavel Andreevich
  • MOROZOV, Dmitry Valentinovich
Agents
  • KONOVALOVA, Ksenia Dmitrievna
Priority Data
202014222021.12.2020RU
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY AND/OR PREVENTION OF SARS-COV-2-RELATED INFECTION
(FR) VACCIN À BASE D'AAV5 POUR INDUCTION D'UNE IMMUNITÉ SPÉCIFIQUE ET/OU PRÉVENTION D'UNE INFECTION LIÉE AU SARS-COV-2
Abstract
(EN) The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated codon-optimized nucleic acid encoding an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to an expression cassette and a vector based thereon, as well as to an AAV5 (adeno-associated virus serotype 5)-based recombinant virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.
(FR) La présente demande concerne les domaines de la biotechnologie, de l'immunologie, de la virologie, de la génétique et de la biologie moléculaire. Plus particulièrement, la présente invention concerne un acide nucléique optimisé par codon isolé codant pour un domaine recombinant isolé de liaison au récepteur de la glycoprotéine S (RBD-S) du SARS-CoV-2 (coronavirus 2 lié au syndrome respiratoire aigu sévère), une cassette d'expression et un vecteur basé sur celle-ci, ainsi qu'à un virus recombinant à base d'AAV5 (virus adéno-associé de sérotype 5) pour l'induction d'une immunité spécifique au SARS-CoV-2 et/ou la prévention de l'infection par le coronavirus lié au SARS-CoV-2, à un vaccin à base d'AAV5 pour l'induction d'une immunité spécifique contre le SRAS-CoV-2 et/ou la prévention de l'infection à coronavirus liée au SRAS-CoV-2, et à leur utilisation pour l'induction d'une immunité spécifique contre le SRAS-CoV-2 et/ou la prévention de l'infection à coronavirus liée au SRAS-CoV-2.
Latest bibliographic data on file with the International Bureau
# -